<DOC>
	<DOCNO>NCT00004013</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Paclitaxel may stop growth breast cancer stop blood flow tumor . PURPOSE : Phase II trial compare effectiveness paclitaxel without trastuzumab follow peripheral stem cell transplantation treat patient refractory stage IV breast cancer .</brief_summary>
	<brief_title>Paclitaxel With Without Trastuzumab Following Peripheral Stem Cell Transplantation Treating Patients With Refractory Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity paclitaxel without trastuzumab follow high dose chemotherapy autologous syngeneic peripheral blood stem cell transplantation patient stage IV breast cancer . II . Assess overall survival patient . OUTLINE : Patients begin study treatment within 50-150 day autologous syngeneic peripheral blood stem cell transplantation . Patients stratify accord overexpression HER2-Neu ( yes v ) , determine type therapy . Arm I ( overexpression HER2-Neu ) : Patients receive paclitaxel IV 60 minute follow initial load dose trastuzumab IV 90 minute . If load dose tolerate well , patient receive maintenance trastuzumab IV 30 minute . Treatment paclitaxel follow maintenance trastuzumab repeat every week 12 week absence disease progression unacceptable toxicity . Arm II ( overexpression Her2-Neu ) : Patients receive paclitaxel IV 60 minute every week 12 week . Patients hormone receptor positive disease also receive antihormonal therapy ( tamoxifen anastrozole ) clinically indicate . Patients isolated metastasis single bone lesion may receive radiotherapy site completion study treatment . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient ( 30 per arm ) accrue study 2-3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Refractory stage IV breast cancer Received high dose chemotherapy ( HDC ) autologous syngeneic peripheral blood stem cell transplantation ( PBSCT ) OR Stage IV breast cancer Failed achieve complete response HDC autologous syngeneic PBSCT initial restaging follow HDC No enrollment protocol FHCRC976 , unless evidence response progressive disease initial restaging follow transplantation Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Platelet count least 50,000/mm3 ( untransfused ) Absolute neutrophil count great 1,000/mm3 ( without filgrastim ( GCSF ) support ) Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : LVEF great 40 % No poorly control arrhythmias No prior coronary artery disease No congestive heart failure within last year No myocardial infarction within past 2 year Other : No active infection No grade 3 regimen related toxicity accord Bearman model No allergy paclitaxel , trastuzumab , benzyl alcohol No grade 3 peripheral neuropathy last chemotherapy HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Concurrent antihormonal therapy ( tamoxifen anastrozole ) allow clinically indicate hormone receptor positive disease Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>